Who are Atropine 0.04%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atropine 0.01%, Slow dose preemptive Atropine, Atropine Sulfate 1% Oph Soln, Atropine Sulfate 01, Atropine Sulfate 03, Atropine Ophthalmic 0.5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atropine-0-04.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Atropine 0.04% — Competitive Intelligence Brief

Atropine 0.04% (Atropine 0.04%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent / Muscarinic antagonist. Area: Ophthalmology.

marketed Anticholinergic agent / Muscarinic antagonist Muscarinic acetylcholine receptors (M1-M5) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Atropine 0.04% (Atropine 0.04%) — Beijing Tongren Hospital. Atropine blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Atropine 0.04% TARGET	Atropine 0.04%	Beijing Tongren Hospital	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine 0.01%	Atropine 0.01%	University Hospital, Strasbourg, France	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Slow dose preemptive Atropine	Slow dose preemptive Atropine	Abant Izzet Baysal University	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine Sulfate 1% Oph Soln	Atropine Sulfate 1% Oph Soln	State University of New York College of Optometry	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1, M3)
Atropine Sulfate 01	Atropine Sulfate 01	LitePharmTech Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine Sulfate 03	Atropine Sulfate 03	LitePharmTech Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine Ophthalmic 0.5%	Atropine Ophthalmic 0.5%	Erasmus Medical Center	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent / Muscarinic antagonist class)

Erasmus Medical Center · 2 drugs in this class
LitePharmTech Co., Ltd. · 2 drugs in this class
Abant Izzet Baysal University · 1 drug in this class
Beijing Tongren Hospital · 1 drug in this class
State University of New York College of Optometry · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atropine 0.04% — Competitive Intelligence Brief. https://druglandscape.com/ci/atropine-0-04. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab